-
-
-
-
-
-
-
Marker Therapeutics (MRKR) PT Raised to $5.60 at Brookline Capital Markets
-
-
-
-
-
-
-
Marker Therapeutics (MRKR) Provides a Clinical Update on MT-601 in Patients with Lymphoma
-
-
-
-
-
-
-
Marker Therapeutics (MRKR) Issues Clinical and Pipeline Update
479,045 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


